FY 2002 |
FY 2003 Current Estimate 2/ |
FY 2004 Request 3/ |
Increase or Decrease |
|
Total Program Level |
||||
|
$39,259,000 |
$40,688,000 |
$40,151,000 |
- $537,000 |
|
221 |
233 |
233 |
0 |
Budget Authority |
$39,259,000 |
$40,688,000 |
$40,151,000 |
- $537,000 |
Cost of Living 1/ |
$588,000 |
+ $588,000 |
||
Homeland Security |
- $21,000 |
- $21,000 |
||
President’s Management Agenda |
||||
|
- $652,000 |
- $652,000 |
||
|
- 5 |
- 5 |
||
|
- $385,000 |
- $385,000 |
||
|
- $67,000 |
- $67,000 |
||
Budget Authority FTE |
221 |
233 |
233 |
0 |
1/ Pay increases shown on separate line and not reflected in individual initiative areas.
2/ Includes technical FTE adjustment to reflect current estimates for FY 2003 burn rate.
3/ Reflects an adjustment to the FY 2003 base for the transfer of $21,000 to the Department of Homeland Security.
Fiscal Year |
Program Level |
Budget Authority |
User Fee |
Program Level FTE |
---|---|---|---|---|
2000 Actual |
$36,522,000 |
$36,522,000 |
0 |
217 |
2001 Actual |
$36,248,000 |
$36,248,000 |
0 |
206 |
2002 Actual4/ |
$39,259,000 |
$39,259,000 |
0 |
221 |
2003 Estimate |
$40,688,000 |
$40,688,000 |
0 |
233 |
2004 Estimate |
$40,151,000 |
$40,151,000 |
0 |
233 |
4/ Includes FDA’s FY 2002 appropriation and the Counterterrorism Supplemental.
FDA's request for funds to cover pay cost increases is essential to accomplishing its mission. Without a specially trained national cadre of scientific staff, FDA’s ability to adequately carry out the mission of protecting public health and providing consumer safety will be compromised. FDA must maintain staffing levels and scientific capabilities that meet the demands of an increasing workload and new challenges, while facing the reality of a competing tight labor market. Payroll costs significantly impact all FDA activities as it accounts for over 60 percent of the Agency’s total budget.
With the pay increases, the Agency can support its ability to fulfill its mission of protecting the public health. The NCTR portion of this increase is $588,000. Without the pay increase, the significant inroads that were made with the counterterrorism supplemental will significantly reduce the FDA’s ability to fulfill its mission to protect the public health by helping safe and effective products reach the market in a timely way, and monitoring products for continued safety after they are in use.
Reflects an adjustment of $583,000 to the FY 2003 base in support of the Department of Homeland Security (DHS). DHS will distribute these funds to States and major cities to support counterterrorism activities such as increased preparedness by hospitals and public health systems. The objective is to improve local preparedness, with national resources ready to be deployed immediately whenever and wherever needed. The NCTR portion of this is $21,000.
The President's Management Agenda, announced in the summer of 2001, is an aggressive strategy for improving the management of the Federal government. It focuses on five areas of management weakness across the government where improvements and the most progress can be made to deliver results to the American people. It reflects the Administration’s commitment to achieve immediate, concrete, and measurable results in the near term, while focusing on remedies to serious problems, and commits to implement them fully. The following areas are FDA’s contribution in FY 2004 towards meeting this aggressive strategy.
FDA has taken FTE reductions across the board, in the centers, field, and administrative areas. The FTE in FDA's counterterrorism program were not affected by the management savings. The current freeze on administrative hiring will be helpful in reaching our FTE reduction, by not filling current vacant positions. Both administrative and scientific positions will be reduced through retirement and attrition.
While it is critical that FDA have the staffing levels to address added responsibility as a result of recent Congressional action, including the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, FDA believes the FTE reductions have been equitably taken across all areas, except for counterterrorism. The NCTR portion of this is $652,000 and 5 FTE.
FDA's FY 2004 President's Budget includes funding to support Departmental efforts to improve the HHS Information Technology Enterprise Infrastructure. The request includes funds to support an enterprise approach to investing in key information technology infrastructure such as security and network modernization. These investments will enable DHHS programs to carryout their missions more securely and at a lower cost. Agency funds will be combined with resources in the Information Technology Security and Innovation Fund to promote collaboration in planning and project management and to achieve common goals such as secure and reliable communication and lower costs for the purchase and maintenance of hardware and software.
FDA's budget request to Congress includes savings totaling $29,587,000 million in the IT budget from both ongoing IT infrastructure consolidation efforts ($15,000,000) as well as reduced developmental costs through the consolidation, streamlining, postponement or elimination of specific lower priority projects ($14,587,000). Of the total IT budget reduction, NCTR accounts for $226,000 in IT infrastructure consolidation costs and $159,000 from reductions in developmental costs to Center and Field systems.
The Agency will fully implement its IT infrastructure consolidation by October 2003, therefore reducing infrastructure expenditure in FY 2004. The CIO's office will look for opportunities that, based on a sound business approach using a rigorous cost benefit analysis, would benefit from the integration of new technology. FDA seeks to reduce spending on specific systems across the entire Agency by identifying savings through one of three rationales: consolidation or the combining of similar systems either within FDA/DHHS that will provide savings and reduce potential unnecessary duplication; streamlining or improved work processes and better project management; and, postponement or elimination of lower priority projects. These improved processes will ensure that the Agency commits to the right projects for the right cost.
As part of the Administration's goals to improve management operations of the Department of Health and Human Services, FDA has been actively implementing the initiatives as included in our restructuring plan submitted to the Department of Health and Human Services on November 30, 2001. To reflect these restructuring efforts the FY 2004 budget request was adjusted for NCTR for the following restructurings:
Rapid response to a terrorist attack is often times the means by which we protect millions of Americans from further exposure to biowarfare agents. It is always the goal of FDA to maintain homeland security by actively seeking new technologies to detect and prevent deliberate contamination of FDA-regulated products. As a part of FDA’s goal to protect the American public, NCTR continues to conduct fundamental applied research aimed at understanding critical biological events to determine how people are adversely affected by exposure to FDA-regulated products and to develop a means by which biowarfare agents can be rapidly detected.
Since foods continue to be susceptible to an ever‑growing variety of potentially hazardous substances including microbial pathogens, chemical residues, natural toxins, and illegal food additives, FDA has an enormous responsibility that has a direct impact on the health of every man, woman and child in the nation. NCTR devotes considerable staff and resources to the discovery and development of new technologies aimed at detecting and eliminating the hazards of foodborne contaminants.
FDA must maintain its ability to protect the public health in a time of rapidly changing technology. To meet this need, NCTR’s highly qualified staff of scientists works to develop innovative new technologies to assist FDA product centers to make sound, science-based regulatory decisions, and to promote the health of the American people through FDA’s core activities of premarket review and postmarket surveillance.
NCTR provides the scientific findings used by FDA product centers for premarket application review and product safety assurance to the scientific community for the betterment of public health. NCTR develops methods to manage or assess risk associated with products that have been adulterated, intentionally contaminated, or found to be detrimental to human health.
Initiative |
FY 2004 Increase Request |
Goal* |
Goal Citation |
---|---|---|---|
Counterterrorism |
NA |
Develop new strategies and methods to test/predict toxicity and assess/detect risk for FDA-regulated products (new and on the market). Catalogue biomarkers and develop standards to establish risk in a bioterrorism environment. |
Strategic Goal #1
Performance Goal #16012 |
Food Safety |
NA |
Develop risk assessment methods and build biological dose-response models in support of the Food Safety Initiative. |
Performance Goal #16007 |
New Technologies |
NA |
Develop computer-based models and infrastructure to predict the health risk of biologically active products. |
Performance Goal #16003 |
Medical Product Safety |
NA |
Develop new strategies and methods to test/predict toxicity and assess/detect risk for FDA-regulated products (new and on the market). Study the risk associated with how a FDA regulated compound or product interacts with the human body. |
Strategic Goal # l
Performance Goal #16004 |
* Goal is expected to be accomplished with base funding.
Program Output | FY 2002 Actuals | FY 2003 Estimate | FY 2004 Estimate |
---|---|---|---|
Research “Accepted” Publications |
185 |
200 |
200 |
Scientific Presentations |
412 |
430 |
430 |
Patents (Industry) |
5 |
5 |
5 |
Interagency Agreements (IAG)* |
8 |
4 |
3 |
Cooperative Research & Development Agreements |
6 |
3 |
2 |
Total Ongoing Research Projects |
210 |
217 |
246 |
*One IAG includes 28 separate projects |
FDA Home Page | Search | A-Z Index | Site Map | Contact FDA
OC/OFM
Web page edited by sml
02/25/2003